Pharmacotherapy of cognitive deficits in schizophrenia

CNS Spectrums

Volumn 19, Issue 2, 2014, Pages 142-156

  Opler, Lewis A ^a,b   Medalia, Alice ^a   Opler, Mark G ^b   Stahl, Stephen M ^c  

^a NewYork Presbyterian Hospital   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Clinical trials; cognitive deficits; MATRICS; pharmacotherapy; schizophrenia

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ABT 126; BRADANICLINE; BUSPIRONE; CHOLINESTERASE INHIBITOR; DEXAMPHETAMINE; DIHYDREXIDINE; DIMEBON; DONEPEZIL; DOPAMINE 1 RECEPTOR STIMULATING AGENT; ENCENICLINE; FLUMAZENIL; FLUPHENAZINE; HALOPERIDOL; LORAZEPAM; MK 0777; MUSCARINIC AGENT; NEUROLEPTIC AGENT; NICOTINIC AGENT; ONDANSETRON; PLACEBO; PREGNENOLONE; RISPERIDONE; RIVASTIGMINE; SEROTONIN 1A AGONIST; SEROTONIN 3 AGONIST; TANDOSPIRONE; TROPISETRON; UNCLASSIFIED DRUG; UNINDEXED DRUG; XANOMELINE; ATYPICAL ANTIPSYCHOTIC AGENT; GLUTAMATE RECEPTOR AGONIST; MINOCYCLINE; PRASTERONE; SEROTONIN ANTAGONIST; VALACICLOVIR; PSYCHOTROPIC AGENT; RECEPTOR;

ADD ON THERAPY; COGNITIVE DEFECT; DRUG APPROVAL; DRUG DOSE COMPARISON; HUMAN; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SINGLE DRUG DOSE; TREATMENT OUTCOME; ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; NONHUMAN; POSITIVE SYNDROME; TREATMENT RESPONSE; BIOLOGICAL MODEL; BRAIN; METABOLISM; NERVE CELL; NEUROPSYCHOLOGICAL TEST; PATHOLOGY; PHYSIOLOGY; SYNAPTIC TRANSMISSION;

BRAIN; COGNITION DISORDERS; DRUG APPROVAL; HUMANS; MODELS, BIOLOGICAL; NEURONS; NEUROPSYCHOLOGICAL TESTS; PSYCHOTROPIC DRUGS; RECEPTORS, BIOGENIC AMINE; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION;

EID: 84901725044     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852913000771     Document Type: Review

References (67)

1. Medalia A, Revheim N. Dealing with Cognitive Dysfunction Associated with Psychiatric Disabilities: A Handbook for Families and Friends of Individuals with Psychiatric Disorders. Albany, NY: New York State Office of Mental Health; 2002.
2. Green MF, Kern RS, Heaton RK. Longitudinal studies of cognition and functional outcome in schizophrenia: Implications for MATRICS. Schizophr Res. 2004; 72(1): 41-51. (Pubitemid 39452904)
3. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996; 153(3): 321-330. (Pubitemid 26074706)
4. Marder SR, Fenton W. Measurement and treatment research to improve cognition in schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophr Res. 2004; 72(1): 5-9. (Pubitemid 39452900)
5. Tamminga CA. The neurobiology of cognition in schizophrenia. J Clin Psychiatry. 2006; 67(9): 9-13. (Pubitemid 44369649)
6. Marder SR. The NIMH-MATRICS project for developing cognitionenhancing agents for schizophrenia. Dialogues Clin Neurosci. 2006; 8(1): 109-113.
7. Arnsten AF, Cai JX, Murphy BL, Goldman-Rakia PS. Dopamine D1 receptor mechanism in the cognitive performance of young adult and aged monkeys. Psychopharmacology (Berl). 1994; 116(2): 143-151. (Pubitemid 24317040)
8. Goldman-Rakic PS, Muly EC, Williams GV. D1 receptors in prefrontal cells and circuits. Brain Res Brain Res Rev. 2000; 31(2-3): 295-301.
9. Barch DM, Carter CS. Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers. Schizophr Res. 2005; 77(1): 43-58. (Pubitemid 40957060)
10. George MS, Molnar CE, Grenesko EL, et al. A single 20mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia. Schizophr Res. 2007; 93(1-3): 42-50. (Pubitemid 46817947)
11. Sumiyoshi T, Park S, Jayathilake K, et al. Effect of buspirone, a serotonin1A agonist, on cognitive function in schizophrenia: A randomized, double-blind, placebo-controlled study. Schizophr Res. 2007; 95(1-3): 158-168. (Pubitemid 47313647)
12. Sumiyoshi T, Matsui M, Nohara S, et al. Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry. 2001; 158(10): 1722-1725. (Pubitemid 32923670)
13. Sumiyoshi T, Matsui M, Yamashita I, et al. The effect of tandospirone, a serotonin(1A) agonist, on memory function in schizophrenia. Biol Psychiatry. 2001; 49(10): 861-868. (Pubitemid 32436390)
14. Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: Their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2003; 27(7): 1159-1172. (Pubitemid 37464960)
15. Akhondzadeh S, Mohammadi N, Noroozian M, et al. Added ondansetron for stable schizophrenia: A double blind, placebo controlled trial. Schizophr Res. 2009; 107(2-3): 206-212.
16. Morozova MA, Beniashvili AG, Lepilkina TA, Rupchev GE. Double-blind placebo-controlled randomized efficacy and safety trial of add-on treatment of dimebon plus risperidone in schizophrenic patients during transition from acute psychotic episode to remission. Psychiatr Danub. 2012; 24(2): 159-166.
17. Morozova MA, Lepilkina TA, Rupchev G, et al. Add-on effects of selective antagonist of 5-HT6 receptors AVN-211 (CD-008-0173) in patients with schizophrenia stabilized on antipsychotic treatment: pilot study. CNS Spectr. 2013; June 17 (Epub ahead of print).
18. Efficacy study exploring the effect of Lu AE58054 as augmentation therapy in patients with schizophrenia. ClinicalTrials.gov. Identifier: NCT00810667.
19. Barr RS, Culhave MA, Jubelt LE, et al. The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls. Neuropsychopharmacology. 2008; 33(3): 480-490.
20. Zhang XY, Liu L, Hong X, et al. Short-term tropisetron treatment and cognitive and p50 auditory gating deficits in schizophrenia. Am J Psychiatry. 2012; 169(9): 974-981.
21. Macor JE, Gurley D, Lanthorn T, et al. The 5-HT3 antagonist tropisetron (ICS 205-930) is a potent and selective alpha-7 nicotinic receptor partial agonist. Bioorg Med Chem Lett. 2001; 11(3): 319-321. (Pubitemid 32115836)
22. Hufford M, Gawryl M, Dgetluck N, et al. Methodological issues affecting signal detection in a clinical trial for cognitive impairment in schizophrenia. Poster Abstracts, ISCTM 8th Annual Scientific Meeting; 21-23 February, 2012; Washington D.C.
23. Radek RJ, Kohlhaas KL, Rueter LE, Mohler EG. Treating the cognitive deficits of schizophrenia with alpha4beta2 neuronal nicotinic receptor agonists. Curr Pharm Des. 2010; 16(3): 309-322.
24. A phase 2 study to evaluate ABT-126 for the treatment of cognitive deficits in schizophrenia. ClinicalTrials.gov. Identifier: NCT01678755.
25. Lieberman JA, Dunbar G, Segreti AC, et al. A randomized exploratory trial of an alpha-7 nicotinic receptor agonist (tc-5619) for cognitive enhancement in schizophrenia. Neuropsychopharmacology. 2013; 38(6): 968-975.
26. Shekhar A, Potter WZ, Lightfoot J, et al. Selective muscarinic receptor agonist xanomeline as a novel treatment approach to schizophrenia. Am J Psychiatry. 2008; 165(8): 1033-1039.
27. Scarr E. Muscarinic M1 receptor agonists: can they improve cognitive performance? Int J Neuropsychopharmacol. 2013; 16(4): 717-720.
28. Lee BJ, Lee JG, Kim YH. A 12-week, double-blind, placebocontrolled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia. J Psychopharmacol. 2007; 21(4): 421-427.
29. Freudenreich O, Herz L, Deckersbach T, et al. Added donepezil for stable schizophrenia: A double-blind, placebo-controlled trial. Psychopharmacology. 2005; 181(2): 358-363. (Pubitemid 41492206)
30. Kohler CG, Martin EA, Kujawski E, et al. No effect of donepezil on neurocognition and social cognition in young persons with stable schizophrenia. Cognit Neuropsychiatry. 2007; 12(5): 412-442.
31. Sharma T, Reed C, Aasen I, Kumari V. Cognitive effects of adjunctive 24-weeks rivastigmine treatment to antipsychotics in schizophrenia: A randomized, placebo-controlled, double-blind investigation. Schizophr Res. 2006; 85(1-3): 73-83. (Pubitemid 43947524)
32. Chouinard S, Stip E, Poulin J, et al. Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits. Curr Med Res Opin. 2007; 23(3): 575-583. (Pubitemid 46456905)
33. Schubert MH, Young KA, Hicks PB. Galantamine improves cognition in schizophrenic patients stabilized on risperidone. Biol Psychiatry. 2006; 60(6): 530-533. (Pubitemid 44402376)
34. Lee SW, Lee JG, Lee BJ, Kim YH. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia. Int Clin Psychopharmacol. 2007; 22(2): 63-68.
35. Woodruff-Pak DS, Vogel RW, Wenk GL. Galantamine: effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning. Proc Natl Acad Sci U S A. 2001; 98(4): 2089-2094. (Pubitemid 32165627)
36. Luby ED, Gottlieb JS, Cohen BD, Rosenbaum G, Domino EF. Model psychoses and schizophrenia. Am J Psychiatry. 1962; 119(1): 61-67.
37. Domino EF, Luby ED. Phencyclidine/schizophrenia: one view toward the past, the other to the future. Schizophr Bull. 2012; 38(5): 914-919.
38. Javitt DC, Jotkowitz A, Sircar R, Zukin SR. Non-competitive regulation of phencyclidine/sigma-receptors by the N-methyl-Daspartate receptor antagonist D-(-)-2-Amino-5-phosphonovaleric acid. Neurosci Lett. 1987; 78(2): 193-198. (Pubitemid 17095698)
39. Javitt DC, Zukin SR. Interaction of [3H]MK-801 with multiple states of the N-methyl-D-Aspartate receptor complex of rat brain. Proc Natl Acad Sci U S A. 1989; 86(2): 740-744. (Pubitemid 19037817)
40. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991; 148(10): 1301-1308.
41. Berk M, Copolov D, Dean O, et al. N-Acetyl cysteine as a glutathione precursor for schizophrenia-A double-blind, randomized, placebo-controlled trial. Biol Psychiatry. 2008; 64(5): 361-368.
42. Lavoie S, Murray MM, Deppen P, et al. Glutathione precursor, n-Acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology. 2008; 33(9): 2187-2199. (Pubitemid 351992093)
43. Goff DC, Cather C, Gottlieb JD, et al. Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study. Schizophr Res. 2008; 106(2-3): 320-327.
44. Mezler M, Geneste H, Gault L, Marek GJ. LY2140023, a prodrug of the group II metabotropic glutamate receptor agonist LY-404039 for the potential treatment of schizophrenia. Curr Opin Investig Drugs. 2010; 11(7): 833-845.
45. Malinow R, Malenka RC. AMPA receptor trafficking and synaptic plasticity. Annu Rev Neurosci. 2002; 25: 103-126. (Pubitemid 34748013)
46. Meador-Woodruff JH, Healy DJ. Glutamate receptor expression in schizophrenic brain. Brain Res Rev. 2000; 31(2-3): 288-294. (Pubitemid 30136183)
47. Goff DC, Leahy L, Berman I, et al. A placebo-controlled pilot study of the ampakine, CX516, added to clozapine in schizophrenia. J Clin Psychopharmacol. 2001; 21(5): 484-487. (Pubitemid 32937430)
48. Goff DC, Lamberti S, Leon AC, et al. A placebo-controlled add-on trial of the ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacology. 2008; 33(3): 465-472.
49. A study of the effect of RO4917838 on biomarker measures of cognitive dysfunction in patients with schizophrenia. ClinicalTrials.gov. Identifier: NCT01116830.
50. Kantrowitz JT, Malhotra AK, Cornblatt B, et al. High dose D-serine in the treatment of schizophrenia. Schizophr Res. 2010; 121(1-3): 125-130.
51. Menzies L, Ooi C, Kamath S, et al. Effects of gamma-Aminobutyric acid-modulating drugs on working memory and brain function in patients with schizophrenia. Arch Gen Psychiatry. 2007; 64(2): 156-167. (Pubitemid 46220773)
52. Lewis DA, Cho RY, Carter CS, et al. Subunit-selective modulation of GABA type A neurotransmission and cognition in schizophrenia. Am J Psychiatry. 2008; 165(12): 1585-1593.
53. Buchanan RW, Keefe RS, Lieberman JA, et al. A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol Psychiatry. 2011; 69(5): 442-449.
54. Keefe RS, Bilder RM, Davis SM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry. 2007; 64(6): 633-647. (Pubitemid 46878665)
55. Keefe RS, Sweeney JA, Hongbin G, et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: A randomized double-blind 52-week comparison. Am J Psychiatry. 2007; 164(7): 1061-1071. (Pubitemid 47121395)
56. Goldberg TE, Goldman RS, Burdick KF, et al. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: Is it a practice effect? Arch Gen Psychiatry. 2007; 64(10): 1115-1122. (Pubitemid 47529336)
57. Ritsner MS, Gibel A, Ratner Y, Tsinovoy G, Strous RD. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: A randomized, double-blind, placebo-controlled, crossover trial. J Clin Psychopharmacol. 2006; 26(5): 495-499. (Pubitemid 44401470)
58. Ritsner MS, Gibel A, Shleifer T, et al. Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, doubleblind, randomized, controlled, 2-center, parallel-group trial. J Clin Psychiatry. 2010; 71(10): 1351-1362.
59. Levkovitz Y, Medlovich S, Riskes S, et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry. 2010; 71(2): 138-149.
60. Cho SJ, Yook K, Kim B, et al. Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: A randomized controlled trial. Prog Neuropsychopharmacol Biol Psychiatry. 2011; 35(1): 208-211.
61. Stenberg J-H, Terevnikov V, Joffe M, et al. Predictors and mediators of add-on mirtazapine-induced cognitive enhancement in schizophrenia-A path model investigation. Neuropharmacology. 2013; 64: 248-253.
62. Scoriels L, Jones PB, Sahakian BJ. Modafanil effects on cognition and emotion in schizophrenia and its neurochemical modulation in the brain. Neuropharmacology. 2013; 64: 168-184.
63. Prasad KM, Eack SM, Keshavan JS, et al. Antiherpes virus-specific treatment and cognition in schizophrenia: A test-of-concept randomized double-blind placebo-controlled trial. Schizophr Bull. 2013; 39(4): 857-866.
64. Goff DC, Hill M, Barch B. The treatment of cognitive impairment in schizophrenia. Pharmacol Biochem Behav. 2011; 99(2): 245-253.
65. Fioravanti M, Bianchi V, Cinti ME. Cognitive deficits in schizophrenia: an updated metanalysis of the scientific evidence. BMC Psychiatry. 2012; 12: 64.
66. Medalia A, Opler MG, Opler LA. Integrating psychopharmacology and cognitive remediation to treat cognitive dysfunction in the psychotic disorders. In: de Oliveira IR, Schwartz T, Stahl SM, eds. Integrating Psychotherapy and Psychopharmacology: A Handbook for Clinicians, New York, NY: Routledge Books; In press.
67. Medalia A, Opler LA, Saperstein A. Integrating psychopharmacology and cognitive remediation to treat cognitive dysfunction in the psychotic disorders. CNS Spectr. 2013, July 23; 1-6 (Epub ahead of print).